FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089930892> ?p ?o ?g. }

• W3089930892 endingPage "4639" @default.
• W3089930892 startingPage "4632" @default.
• W3089930892 abstract "Abstract Anticoagulant treatment of pediatric central venous catheter–related venous thromboembolism (CVC-VTE) has not been specifically evaluated. In EINSTEIN-Jr, 500 children with any VTE received rivaroxaban or standard anticoagulants. A predefined analysis of the CVC-VTE cohort was performed. Children with CVC-VTE (age, birth to 17 years) were administered rivaroxaban or standard anticoagulants during the 1-month (children &lt;2 years) or 3-month (all other children) study period. Predefined outcomes were recurrent VTE, change in thrombotic burden on repeat imaging, and bleeding. Predictors for continuation of anticoagulant therapy beyond the study period were evaluated. One hundred twenty-six children with symptomatic (n = 76, 60%) or asymptomatic (n = 50, 40%) CVC-VTE received either rivaroxaban (n = 90) or standard anticoagulants (n = 36). There was no recurrent VTE (0%; 95% confidence interval [CI], 0.0%-2.8%). Three children had the principal safety outcome: none had major bleeding and 3 children had clinically relevant nonmajor bleeding (2.4%; 95% CI, 0.7%-6.5%), all in the rivaroxaban arm. Complete or partial vein recanalization occurred in 57 (55%) and 38 (37%) of 103 evaluable children, respectively. Results were similar for symptomatic and asymptomatic CVC-VTE. Continuation of anticoagulant therapy beyond the study period occurred in 61 (48%) of children and was associated with residual VTE but only in children &lt;2 years (odds ratio [OR], 20.9; P = .003) and continued CVC use (OR, 6.7; P = .002). Anticoagulant therapy appeared safe and efficacious and was associated with reduced clot burden in most children with symptomatic or asymptomatic CVC-VTE. Residual VTE and continued CVC use were associated with extended anticoagulation. This trial was registered at www.clinicaltrials.gov as #NCT02234843." @default.
• W3089930892 created "2020-10-08" @default.
• W3089930892 creator A5004338432 @default.
• W3089930892 creator A5015664623 @default.
• W3089930892 creator A5015924493 @default.
• W3089930892 creator A5020376174 @default.
• W3089930892 creator A5024307257 @default.
• W3089930892 creator A5027693628 @default.
• W3089930892 creator A5028466630 @default.
• W3089930892 creator A5034215158 @default.
• W3089930892 creator A5038720349 @default.
• W3089930892 creator A5039204383 @default.
• W3089930892 creator A5040870075 @default.
• W3089930892 creator A5044350124 @default.
• W3089930892 creator A5052869655 @default.
• W3089930892 creator A5055052720 @default.
• W3089930892 creator A5058130927 @default.
• W3089930892 creator A5059160803 @default.
• W3089930892 creator A5070607078 @default.
• W3089930892 creator A5072459334 @default.
• W3089930892 creator A5073005901 @default.
• W3089930892 creator A5082783229 @default.
• W3089930892 creator A5084922482 @default.
• W3089930892 creator A5085021795 @default.
• W3089930892 creator A5088928765 @default.
• W3089930892 creator A5090277200 @default.
• W3089930892 creator A5090622562 @default.
• W3089930892 date "2020-09-30" @default.
• W3089930892 modified "2023-10-02" @default.
• W3089930892 title "Safety and efficacy of anticoagulant therapy in pediatric catheter-related venous thrombosis (EINSTEIN-Jr CVC-VTE)" @default.
• W3089930892 cites W1770147359 @default.
• W3089930892 cites W181091954 @default.
• W3089930892 cites W1982356022 @default.
• W3089930892 cites W1983000651 @default.
• W3089930892 cites W2002808378 @default.
• W3089930892 cites W2057902183 @default.
• W3089930892 cites W2070230602 @default.
• W3089930892 cites W2078687955 @default.
• W3089930892 cites W2104944704 @default.
• W3089930892 cites W2106459062 @default.
• W3089930892 cites W2115787552 @default.
• W3089930892 cites W2117662968 @default.
• W3089930892 cites W2126672009 @default.
• W3089930892 cites W2130199362 @default.
• W3089930892 cites W2143907400 @default.
• W3089930892 cites W2147865643 @default.
• W3089930892 cites W2161499767 @default.
• W3089930892 cites W2315246750 @default.
• W3089930892 cites W2890776880 @default.
• W3089930892 cites W2902418274 @default.
• W3089930892 cites W2903436171 @default.
• W3089930892 cites W2968662162 @default.
• W3089930892 cites W2987943866 @default.
• W3089930892 cites W2999200734 @default.
• W3089930892 cites W3003252954 @default.
• W3089930892 cites W3014334390 @default.
• W3089930892 doi "https://doi.org/10.1182/bloodadvances.2020002637" @default.
• W3089930892 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/7556137" @default.
• W3089930892 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33002131" @default.
• W3089930892 hasPublicationYear "2020" @default.
• W3089930892 type Work @default.
• W3089930892 sameAs 3089930892 @default.
• W3089930892 citedByCount "28" @default.
• W3089930892 countsByYear W30899308922021 @default.
• W3089930892 countsByYear W30899308922022 @default.
• W3089930892 countsByYear W30899308922023 @default.
• W3089930892 crossrefType "journal-article" @default.
• W3089930892 hasAuthorship W3089930892A5004338432 @default.
• W3089930892 hasAuthorship W3089930892A5015664623 @default.
• W3089930892 hasAuthorship W3089930892A5015924493 @default.
• W3089930892 hasAuthorship W3089930892A5020376174 @default.
• W3089930892 hasAuthorship W3089930892A5024307257 @default.
• W3089930892 hasAuthorship W3089930892A5027693628 @default.
• W3089930892 hasAuthorship W3089930892A5028466630 @default.
• W3089930892 hasAuthorship W3089930892A5034215158 @default.
• W3089930892 hasAuthorship W3089930892A5038720349 @default.
• W3089930892 hasAuthorship W3089930892A5039204383 @default.
• W3089930892 hasAuthorship W3089930892A5040870075 @default.
• W3089930892 hasAuthorship W3089930892A5044350124 @default.
• W3089930892 hasAuthorship W3089930892A5052869655 @default.
• W3089930892 hasAuthorship W3089930892A5055052720 @default.
• W3089930892 hasAuthorship W3089930892A5058130927 @default.
• W3089930892 hasAuthorship W3089930892A5059160803 @default.
• W3089930892 hasAuthorship W3089930892A5070607078 @default.
• W3089930892 hasAuthorship W3089930892A5072459334 @default.
• W3089930892 hasAuthorship W3089930892A5073005901 @default.
• W3089930892 hasAuthorship W3089930892A5082783229 @default.
• W3089930892 hasAuthorship W3089930892A5084922482 @default.
• W3089930892 hasAuthorship W3089930892A5085021795 @default.
• W3089930892 hasAuthorship W3089930892A5088928765 @default.
• W3089930892 hasAuthorship W3089930892A5090277200 @default.
• W3089930892 hasAuthorship W3089930892A5090622562 @default.
• W3089930892 hasBestOaLocation W30899308921 @default.
• W3089930892 hasConcept C126322002 @default.
• W3089930892 hasConcept C141071460 @default.
• W3089930892 hasConcept C156957248 @default.
• W3089930892 hasConcept C187212893 @default.
• W3089930892 hasConcept C2776301958 @default.

• next